Advanced search
Publication Cover
Acta Oncologica Volume 52, 2013 - Issue 8
Journal homepage
1,364
Views
39
CrossRef citations to date
0
Altmetric
Acta Oncologica Jubilee Article

Population-based study on use of chemotherapy in men with castration resistant prostate cancer

Ingela Franck LissbrantDepartment of Oncology, Institute of Clinical Sciences, The Sahlgrenska Academy, University of Gothenburg, SwedenCorrespondence[email protected]
,
Hans GarmoKing's College London, School of Medicine, Division of Cancer Studies, Cancer Epidemiology Unit, London, UK;Regional Cancer Centre, Uppsala University Hospital, Uppsala, Sweden
,
Anders WidmarkDepartment of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden
&
Pär StattinDepartment of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden;Department of Surgery, Urology Service, Memorial Sloan-Kettering Cancer Center, New York, USA
Pages 1593-1601 | Received 06 Nov 2012, Accepted 09 Feb 2013, Published online: 21 Feb 2013

Citations (39)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (10)

Anne Holck Storås, Kaitlyn Tsuruda, Sophie Dorothea Fosså & Bettina Kulle Andreassen. (2023) Time trends in systemic treatment for patients with metastatic prostate cancer: a national cohort study. Acta Oncologica 62:12, pages 1716-1722.
Read now
Gunn Ammitzbøll, Anne Katrine Graudal Levinsen, Trille Kristina Kjær, Freja Ejlebæk Ebbestad, Trine Allerslev Horsbøl, Lena Saltbæk, Sara Koed Badre-Esfahani, Andrea Joensen, Eva Kjeldsted, Maja Halgren Olsen & Susanne Oksbjerg Dalton. (2022) Socioeconomic inequality in cancer in the Nordic countries. A systematic review. Acta Oncologica 61:11, pages 1317-1331.
Read now
Tiago M. Bonde, Marcus Westerberg, Markus Aly, Martin Eklund, Jan Adolfsson, Anna Bill-Axelson, Hans Garmo, Pär Stattin & David Robinson. (2022) Time to castration-resistant prostate cancer and prostate cancer death according to PSA response in men with non-metastatic prostate cancer treated with gonadotropin releasing hormone agonists. Scandinavian Journal of Urology 56:3, pages 169-175.
Read now
Hari T. Vigneswaran, Anna Warnqvist, Therese M. L. Andersson, Amy Leval, Martin Eklund, Tobias Nordström, Sandra Eloranta, Frida Schain, Lindsay Dearden, Johan Liwing, Maneesha Mehra, Sandhya Nair, Andreas Pettersson, Olof Akre & Markus Aly. (2021) Real world treatment utilization patterns in patients with castration-resistant prostate cancer. Scandinavian Journal of Urology 55:4, pages 299-306.
Read now
Johanna Svensson, Ingela Franck Lissbrant, Oskar Gauffin, Marie Hjälm-Eriksson, Suzanne Kilany, Karin Fagerlund & Pär Stattin. (2021) Time spent in hormone-sensitive and castration-resistant disease states in men with advanced prostate cancer, and its health economic impact: registry-based study in Sweden. Scandinavian Journal of Urology 55:1, pages 1-8.
Read now
Marcus Westerberg, Ingela Franck Lissbrant, Jan Erik Damber, David Robinson, Hans Garmo & Pär Stattin. (2020) Temporal changes in survival in men with de novo metastatic prostate cancer: nationwide population-based study. Acta Oncologica 59:1, pages 106-111.
Read now
Ingela Franck Lissbrant, Eugenio Ventimiglia, David Robinson, Magnus Törnblom, Marie Hjälm-Eriksson, Mats Lambe, Yasin Folkvaljon & Pär Stattin. (2018) Nationwide population-based study on the use of novel antiandrogens in men with prostate cancer in Sweden. Scandinavian Journal of Urology 52:2, pages 143-150.
Read now
Stina Fuentes & Jan-Erik Frödin. (2015) Why is intravenous chemotherapy cancelled and how often. Could it be prevented? A prospective analysis of all planned and given intravenous anti-tumor treatments at the Department of Oncology, Karolinska University Hospital, Stockholm during one month. Acta Oncologica 54:7, pages 1056-1062.
Read now
Bengt Glimelius. (2014) The 50-year anniversary of Acta Oncologica. Acta Oncologica 53:1, pages 1-2.
Read now
Gunnar Steineck & Bengt Glimelius. (2013) What is the appropriate use of palliative docetaxel in castration-resistant prostate cancer?. Acta Oncologica 52:8, pages 1589-1592.
Read now

Articles from other publishers (29)

Rolf Gedeborg, Fredrik Sandin, Camilla Thellenberg-Karlsson, Johan Styrke, Ingela Franck Lissbrant, Hans Garmo & Pär Stattin. (2023) Uptake of doublet therapy for de novo metastatic castration sensitive prostate cancer: a population-based drug utilisation study in Sweden. Scandinavian Journal of Urology 58.
Crossref
Jason Hu, Armen G. Aprikian, Ramy R. Saleh & Alice Dragomir. (2022) Utilization Trends of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer in Quebec. Current Oncology 29:11, pages 8626-8637.
Crossref
Eugenio Ventimiglia, Anna Bill-Axelson, Jan Adolfsson, Markus Aly, Martin Eklund, Marcus Westerberg, Pär Stattin & Hans Garmo. (2022) Modeling Disease Trajectories for Castration-resistant Prostate Cancer Using Nationwide Population-based Data. European Urology Open Science 44, pages 46-51.
Crossref
Shruti Parshad, Amanjot K. Sidhu, Nabeeha Khan, Andrew Naoum & Urban Emmenegger. (2022) Metronomic Chemotherapy for Advanced Prostate Cancer: A Literature Review. Journal of Clinical Medicine 11:10, pages 2783.
Crossref
Yashar Khoshkar, Marcus Westerberg, Jan Adolfsson, Anna Bill‐Axelson, Henrik Olsson, Martin Eklund, Olof Akre, Hans Garmo & Markus Aly. (2021) Mortality in men with castration‐resistant prostate cancer—A long‐term follow‐up of a population‐based real‐world cohort. BJUI Compass 3:2, pages 173-183.
Crossref
Benedikt Hoeh, Christoph Würnschimmel, Rocco S. Flammia, Benedikt Horlemann, Gabriele Sorce, Francesco Chierigo, Zhe Tian, Fred Saad, Markus Graefen, Michele Gallucci, Alberto Briganti, Carlo Terrone, Shahrokh F. Shariat, Derya Tilki, Luis A. Kluth, Philipp Mandel, Felix K. H. Chun & Pierre I. Karakiewicz. (2021) Improvement in overall and cancer‐specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patients. The Prostate 81:16, pages 1374-1381.
Crossref
Benedikt Hoeh, Christoph Würnschimmel, Rocco S. Flammia, Benedikt Horlemann, Gabriele Sorce, Francesco Chierigo, Zhe Tian, Fred Saad, Markus Graefen, Michele Gallucci, Alberto Briganti, Carlo Terrone, Shahrokh F. Shariat, Derya Tilki, Luis A. Kluth, Philipp Mandel, Felix K. H. Chun & Pierre I. Karakiewicz. (2021) Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer Patients. Frontiers in Oncology 11.
Crossref
Fernando C. Maluf, Fabrício A.M. de Oliveira, Pedro E.R. Liedke, Leandro Brust, Cristina G. Inocêncio, Fernando S.M. Monteiro, Oren Smaletz & Daniel I. Cubero. (2021) Neutropenia Prevention in the Treatment of Post-docetaxel Metastatic, Castration-resistant Prostate Cancer With Cabazitaxel and Prednisone: A Multicenter, Open-label, Single-arm Phase IV Study. Clinical Genitourinary Cancer 19:3, pages e171-e177.
Crossref
Kerri Beckmann, Hans Garmo, Ingela Franck Lissbrant & Pär Stattin. (2021) The Value of Real-World Data in Understanding Prostate Cancer Risk and Improving Clinical Care: Examples from Swedish Registries. Cancers 13:4, pages 875.
Crossref
Cedric Pobel, Edouard Auclin, Adrien Procureur, Alice Clément-Zhao, Audrey Simonaggio, Nicolas Delanoy, Yann-Alexandre Vano, Constance Thibault & Stéphane Oudard. (2021) Cabazitaxel schedules in metastatic castration-resistant prostate cancer: a review. Future Oncology 17:1, pages 91-102.
Crossref
Andri Wilberg Orrason, Marcus Westerberg, Hans Garmo, Ingela Franck Lissbrant, David Robinson & Pär Stattin. (2020) Changes in treatment and mortality in men with locally advanced prostate cancer between 2000 and 2016: a nationwide, population‐based study in Sweden. BJU International 126:1, pages 142-151.
Crossref
Halima Lahcene, Armen G Aprikian, Marie Vanhuyse, Jason Hu, Franck Bladou, Fabio Cury, Wassim Kassouf, Sylvie Perreault & Alice Dragomir. (2019) Impact of the introduction of novel hormonal agents on metastatic castration-resistant prostate cancer treatment choice. Journal of Oncology Pharmacy Practice 26:2, pages 293-305.
Crossref
Inez Charlotte van Walree, Eline L. G. Breukelen, Noortje Thielen, Marcel T. M. Rens, Lieke H. Huis‐Tanja & Marije E. Hamaker. (2019) Chemotherapy in the oldest old: Choices and outcomes. European Journal of Cancer Care 28:4.
Crossref
Cora N Sternberg. (2019) Enzalutamide, an oral androgen receptor inhibitor for treatment of castration-resistant prostate cancer. Future Oncology 15:13, pages 1437-1457.
Crossref
Ruixiao Lu, Rui Tang & Jing Huang. 2019. Statistical Methods in Biomarker and Early Clinical Development. Statistical Methods in Biomarker and Early Clinical Development 137 166 .
E. B. Moth, B. E. Kiely, V. Naganathan, A. Martin & P. Blinman. (2017) How do oncologists make decisions about chemotherapy for their older patients with cancer? A survey of Australian oncologists. Supportive Care in Cancer 26:2, pages 451-460.
Crossref
D. Robert Siemens, Laurence Klotz, Axel Heidenreich, Simon Chowdhury, Arnauld Villers, Benoit Baron, Steve van Os, Nahla Hasabou, Fong Wang, Ping Lin & Neal D. Shore. (2018) Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN Trial. The Journal of Urology 199:1, pages 147-154.
Crossref
Magdalena Lycken, Linda Drevin, Hans Garmo, Pär Stattin, Jan Adolfsson, Ingela Franck Lissbrant, Lars Holmberg & Anna Bill-Axelson. (2018) The use of palliative medications before death from prostate cancer: Swedish population-based study with a comparative overview of European data. European Journal of Cancer 88, pages 101-108.
Crossref
Karim Fizazi, Christophe Massard, Petri Bono, Vesa Kataja, Nicholas James, Teuvo L. Tammela, Heikki Joensuu, John Aspegren & Mika Mustonen. (2017) Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Castration-resistant, CYP17 Inhibitor-naïve Prostate Cancer: Results from Extended Follow-up of the ARADES Trial. European Urology Focus 3:6, pages 606-614.
Crossref
Johann S. de Bono, Matthew R. Smith, Fred Saad, Dana E. Rathkopf, Peter F.A. Mulders, Eric J. Small, Neal D. Shore, Karim Fizazi, Peter De Porre, Thian Kheoh, Jinhui Li, Mary B. Todd, Charles J. Ryan & Thomas W. Flaig. (2017) Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. European Urology 71:4, pages 656-664.
Crossref
Kasper Drimer Berg, Frederik Birkebæk Thomsen, Marta K. Mikkelsen, Inga J. Ingimarsdóttir, Rikke B. Hansen, Anne Mette T. Kejs & Klaus Brasso. (2017) Improved survival for patients with de novo metastatic prostate cancer in the last 20 years. European Journal of Cancer 72, pages 20-27.
Crossref
Jean-Pierre Droz, Eleni Efstathiou, Asif Yildirim, Paula Cabrera, Choung Soo Kim, Ali Horchani, Axel Heidenreich, Jos? Augusto Rinck-Junior, Simon Hitier & Haluk ?zen. (2016) First-line treatment in senior adults with metastatic castration-resistant prostate cancer: A prospective international registry. Urologic Oncology: Seminars and Original Investigations 34:5, pages 234.e21-234.e29.
Crossref
J.N. Graff, G. Baciarello, A.J. Armstrong, C.S. Higano, P. Iversen, T.W. Flaig, D. Forer, T. Parli, D. Phung, B. Tombal, T.M. Beer & C.N. Sternberg. (2016) Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL. Annals of Oncology 27:2, pages 286-294.
Crossref
Thomas W. Flaig, Ravi C. Potluri, Yvette Ng, Mary B. Todd & Maneesha Mehra. (2015) Treatment evolution for metastatic castration‐resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real‐world data. Cancer Medicine 5:2, pages 182-191.
Crossref
E. Feletto, A. Bang, D. Cole-Clark, V. Chalasani, K. Rasiah & D. P. Smith. (2015) An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high?. World Journal of Urology 33:11, pages 1677-1687.
Crossref
Fred Saad, Karim Fizazi, Viorel Jinga, Eleni Efstathiou, Peter C Fong, Lowell L Hart, Robert Jones, Raymond McDermott, Manfred Wirth, Kazuhiro Suzuki, David B MacLean, Ling Wang, Hideyuki Akaza, Joel Nelson, Howard I Scher, Robert Dreicer, Iain J Webb & Ronald de Wit. (2015) Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. The Lancet Oncology 16:3, pages 338-348.
Crossref
Tomasz M. Beer, Andrew J. Armstrong, Dana E. Rathkopf, Yohann Loriot, Cora N. Sternberg, Celestia S. Higano, Peter Iversen, Suman Bhattacharya, Joan Carles, Simon Chowdhury, Ian D. Davis, Johann S. de Bono, Christopher P. Evans, Karim Fizazi, Anthony M. Joshua, Choung-Soo Kim, Go Kimura, Paul Mainwaring, Harry Mansbach, Kurt Miller, Sarah B. Noonberg, Frank Perabo, De Phung, Fred Saad, Howard I. Scher, Mary-Ellen Taplin, Peter M. Venner & Bertrand Tombal. (2014) Enzalutamide in Metastatic Prostate Cancer before Chemotherapy. New England Journal of Medicine 371:5, pages 424-433.
Crossref
John M. Fitzpatrick, Joaquim Bellmunt, Karim Fizazi, Axel Heidenreich, Cora N. Sternberg, Bertrand Tombal, Antonio Alcaraz, Amit Bahl, Sergio Bracarda, Giuseppe Di Lorenzo, Eleni Efstathiou, Stephen P. Finn, Sophie Foss?Silke Gillessen, Pirkko-Liisa Kellokumpu-Lehtinen, Fr?d?ric E. Lecouvet, Stephane Oudard, Theo M. de Reijke, Craig N. Robson, Maria De Santis, Bostjan Seruga & Ronald de Wit. (2014) Optimal management of metastatic castration-resistant prostate cancer: Highlights from a European Expert Consensus Panel. European Journal of Cancer 50:9, pages 1617-1627.
Crossref
Keemo Delos Santos, Lavarnan Sivanathan, Kelly Lien & Urban Emmenegger. 2014. Metronomic Chemotherapy. Metronomic Chemotherapy 119 134 .

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.